A5008870382- Renal cell carcinoma treatment
- Renal and related cancers
- Bladder and Urothelial Cancer Treatments
- Urological Disorders and Treatments
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Urinary and Genital Oncology Studies
- Urologic and reproductive health conditions
- Ureteral procedures and complications
- Genital Health and Disease
- Renal and Vascular Pathologies
- Pediatric Urology and Nephrology Studies
- MRI in cancer diagnosis
- Multiple and Secondary Primary Cancers
- Minimally Invasive Surgical Techniques
- Tuberous Sclerosis Complex Research
- Genetic and Kidney Cyst Diseases
- Education, Psychology, and Social Research
- Sarcoma Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- Pancreatic and Hepatic Oncology Research
- Cancer, Lipids, and Metabolism
- Pelvic and Acetabular Injuries
- Adrenal and Paraganglionic Tumors
Charles University
2016-2025
Institute of Medical Sciences
2024
University Hospital Plzen
2011-2021
University of Calgary
2015
University of Sarajevo
2015
Riga East University Hospital
2015
Development Fund
2015
University Hospital Dubrava
2015
Sisters of Charity Hospital
2015
Centro Médico ABC
2015
The European Association of Urology (EAU) Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management RCC. To present a summary 2022 RCC guideline, which is based on standardised methodology including systematic reviews (SRs) provides transparent reliable evidence For update, new literature search was carried out with cutoff date May 28, 2021, covering Medline, EMBASE, Cochrane databases. data focused randomised controlled trials...
Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR) gene alterations, including